New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
07:19 EDTELN, BIIBBiogen price target raised to $170 from $150 at RBC Capital
After Biogen (BIIB) acquired Elan's (ELN) stake in Tysabri, RBC Capital thinks the deal makes sense from a strategic financial perspective, as it will raise Biogen's margins and lower its tax rate. The firm thinks the company's SG&A as a percentage of revenue will also decline following the deal and it maintains an Outperform rating on the shares.
News For BIIB;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
11:08 EDTBIIBBiogen to add PML info on Tecfidera label after patient dies
Subscribe for More Information
11:04 EDTBIIBFDA says Biogen adding PML information on Tecfidera label
November 24, 2014
07:59 EDTBIIBBiogen resumed with an Outperform at Leerink
Subscribe for More Information
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 13, 2014
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
November 12, 2014
08:13 EDTBIIBBoston Biotech to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use